June 1, 2010 (San Francisco, California) — Transurethral resection of the prostate (TURP) seems to be a better treatment option than medical therapy for patients with benign prostatic hyperplasia (BPH ...

The US Food and Drug Administration (FDA) has cleared Prodeon Medical's implantable technology for treating lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). The ...

BOSTON and YOKNEAM, Israel, April 22, 2025 /PRNewswire/ -- Butterfly Medical, a medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), announced ...

Key goals in the management of BPH are controlling symptoms along with preventing complications and improving quality of life (QOL) of affected individuals. Choosing among the various treatment ...

The term TURP stands for transurethral resection of the prostate, an operation that is mainly performed to treat men with an enlarged prostate, a condition called benign prostate hyperplasia (BPH).

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...

Benign prostatic hyperplasia (BPH) is an extremely common condition among elderly men, reaching a prevalence of approximately 70% in men over age 61 y and of greater than 90% in those over age 80 y. 1 ...

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, ...

Butterfly Medical has raised $21m in Series C funding for the development and potential commercialisation of its minimally invasive device for benign prostatic hyperplasia (BPH). This latest funding ...